london euretina

This meeting has been awarded 20 CME credits

Security Notice

Please note that Kuoni are our only destination management company. Other venders indicating that are operating for the society should be ignored. We never use western union as a payment portal

Posters

Intravitreal bevacizumab combined with or without 532 nm transpupillary laser therapy for Type I retinopathy of prematurity

Poster Details

First Author: E.Aydin TURKEY

Co Author(s):                      0   0 0   0 0   0 0   0 0

Abstract Details



Purpose:

To investigate efficacy of intravitreal enjection of ranizumab and laser photocoagulation for treatment of type I retinopathy of prematurity (ROP) and compare the results in terms of regression and final structural outcome with intravitreal bevacizumab combined with or without conventional transpupillary laser photocoagulation.

Setting:

Retrospective analysis

Methods:

The medical records of 111 eyes of 56 infants with Type I and aggressive ROP, who underwent indirect transpupillary laser or / and intraocular injection of bevacizumab (0.03 mL / 0.75mg), were retrospectively reviewed.

Results:

56 patients with birth weight 790 to 2700 g (mean,1500.2) and with gestastional age 26 to 34 weeks (mean, 30.2) were included in the study. The timing of bevacizumab injection ranged from postmenstrual age 33.2 to 37 weeks. 18 eyes of 9 patients underwent intravitreal injection of bevacizumab. 41 eyes of 21 patients were treated with transpupillary indirect laser. Intravitreal bevacizumab combined with laser ablasion were perfomed in 52 eyes of 26 patients

Conclusions:

Intravitreal bevacizumab combined with or without laser ablasion seems to be highly effective and well tolerated method of treatment in the patients with Type I retinopathy of premature. Inadequate response to treatment of patients with aggressive ROP may need vitreoretinal surgery in a few cases.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy